Yukiguni Factory Co., Ltd.

2026/08/06 Updated
Market Cap: $286.5M (¥45.2B)
Stock Price: $7.18 (¥1,133)
Exchange Rate: 1 USD = ¥157.73

FY2027 First Quarter Results for the Period Ended March 2027

The consolidated results for the first quarter of the fiscal year ending March 2027 show net sales of 7,983 million yen (up 9.6% YoY), total revenue of 10,202 million yen, core EBITDA of 831 million yen (margin 10.4%), operating loss of 433 million yen, and quarterly net loss attributable to owners of the parent of 306 million yen. Gains from fair value changes contributed 2,218 million yen to net sales. Full-year guidance remains as previously disclosed. The company is advancing stronger R&D capabilities and the opening of new facilities to strengthen its medium- to long-term growth base.

Importance:
Page Updated: August 6, 2026
IR Disclosure Date: August 6, 2026

Key Figures

  • Net sales: 7,983 million yen (YoY +9.6%)
  • Total revenue: 10,202 million yen (YoY +15.4%)
  • Operating loss, net loss attributable to owners of the parent: △433 million yen, △306 million yen
  • Gain from fair value changes: 2,218 million yen (YoY +42.8%)
  • Segment sales: Mushroom business overall solid (details: Maitake, Eringi, Bunashimeji, and others)

AI要約

Section heading

Summary of the results: net sales of 7,983 million yen, total revenue of 10,202 million yen, core EBITDA of 831 million yen, and core EBITDA margin of 10.4%. Gains from fair value changes contributed 2,218 million yen, significantly supporting results, with year-over-year sales increase. However, operating loss remained 433 million yen and quarterly net loss attributable to owners of the parent was 306 million yen. Strengthening R&D investment and the establishment of new facilities are expected to reinforce the mid- to long-term growth trajectory.

Section 2 heading

Segment-wise, the mushroom business overall remained solid, with gains in Maitake, Eringi, Bunashimeji, and other mushrooms. By strengthening the R&D and Business Development divisions and leveraging the new facility 'Kinomi Life Lab,' the company aims to accelerate innovation creation and market expansion. The consolidated forecast remains in line with previous guidance, and capital investments will continue based on a long-term growth strategy.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Yukiguni Factory Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →